UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Cochrane database of systematic reviews, 2017-01, Vol.1 (1), p.CD012040

2017

Volltextzugriff (PDF)

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

The Journal of pediatrics, 2017-02, Vol.181, p.S4-S15.e1

2017

Volltextzugriff (PDF)

Newborn screening for cystic fibrosis

The lancet respiratory medicine, 2016-08, Vol.4 (8), p.653-661

2016

Volltextzugriff (PDF)

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

Cochrane database of systematic reviews, 2020-12, Vol.12 (12), p.CD010966-CD010966

2020

Volltextzugriff (PDF)

Autogenic drainage for airway clearance in cystic fibrosis

Cochrane database of systematic reviews, 2017-10, Vol.10 (10), p.CD009595

2017

Volltextzugriff (PDF)

Achieving respiratory excellence in pre-school children with cystic fibrosis

Journal of cystic fibrosis, 2021-11, Vol.20 (6), p.904-905

Southern, Kevin W

2021

Volltextzugriff (PDF)

Receiving results of uncertain clinical relevance from population genetic screening: systematic review & meta-synthesis of qualitative research

European journal of human genetics : EJHG, 2022-05, Vol.30 (5), p.520-531

2022

Volltextzugriff (PDF)

Future therapies for cystic fibrosis

Nature communications, 2023-02, Vol.14 (1), p.693-693, Article 693

2023

Volltextzugriff (PDF)

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Cochrane database of systematic reviews, 2022-09, Vol.9 (9), p.CD002204

2022

Volltextzugriff (PDF)

Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis

The Journal of pediatrics, 2017-02, Vol.181, p.S45-S51.e1

2017

Volltextzugriff (PDF)

Macrolide antibiotics for cystic fibrosis

Cochrane database of systematic reviews, 2012-11, Vol.11, p.CD002203

2012

Volltextzugriff (PDF)

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

The lancet respiratory medicine, 2016-02, Vol.4 (2), p.107-115

2016

Volltextzugriff (PDF)

Impact of COVID-19 on people with cystic fibrosis

The lancet respiratory medicine, 2020-05, Vol.8 (5), p.e35-e36

2020

Volltextzugriff (PDF)

Raised Intracranial Pressure in Three Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Modulator Therapy

American journal of respiratory and critical care medicine, 2023-07, Vol.208 (1), p.103-105

2023

Volltextzugriff (PDF)

ECFS best practice guidelines: the 2018 revision

Journal of cystic fibrosis, 2018-03, Vol.17 (2), p.153-178

2018

Volltextzugriff (PDF)

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Cochrane database of systematic reviews, 2023-03, Vol.3 (3), p.CD012040-CD012040

2023

Volltextzugriff (PDF)

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

Cochrane database of systematic reviews, 2023-11, Vol.11 (11), p.CD010966

2023

Volltextzugriff (PDF)

COVID-19 infection in children

The lancet respiratory medicine, 2020-05, Vol.8 (5), p.446-447

2020

Volltextzugriff (PDF)

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Cochrane database of systematic reviews, 2016-11, Vol.11 (11), p.CD002204

2016

Volltextzugriff (PDF)

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

Cochrane database of systematic reviews, 2018-08, Vol.8 (8), p.CD010966

2018

Volltextzugriff (PDF)

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

Journal of cystic fibrosis, 2014-05, Vol.13, p.S23-S42

2014

Volltextzugriff (PDF)

Exercise versus airway clearance techniques for people with cystic fibrosis

Cochrane database of systematic reviews, 2022-06, Vol.6 (6), p.CD013285-CD013285

2022

Volltextzugriff (PDF)

Development and validation of a short form psychometric tool assessing the caregiving Challenge of Living with Cystic Fibrosis (CLCF-SF) in a child

Psychology & health, 2023-07, Vol.ahead-of-print (ahead-of-print), p.1-23

2023

Volltextzugriff (PDF)

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis

Cochrane database of systematic reviews, 2019-01, Vol.1 (1), p.CD009841

2019

Volltextzugriff (PDF)

Parental decision-making and acceptance of newborn bloodspot screening: an exploratory study

PloS one, 2013-11, Vol.8 (11), p.e79441-e79441

2013

Volltextzugriff (PDF)

1 – 25 von 269

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(234)
Mit Volltextzugriff
(210)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(268)
Polnisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(188)
Life Sciences & Biomedicine
(173)
Humans
(125)
Cystic Fibrosis
(82)
Respiratory System
(56)
General & Internal Medicine
(47)
Male
(46)
Female
(43)
Adult
(42)
Child
(42)
Medicine, General & Internal
(34)
Pediatrics
(34)
Cystic Fibrosis - Genetics
(32)
Biological And Medical Sciences
(30)
Infant, Newborn
(30)
Cystic Fibrosis - Drug Therapy
(28)
Cystic Fibrosis - Complications
(27)
Cystic Fibrosis - Diagnosis
(25)
Cystic Fibrosis Transmembrane Conductance Regulator - Genetics
(22)
Adolescent
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

Newborn screening for cystic fibrosis

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

Autogenic drainage for airway clearance in cystic fibrosis

Achieving respiratory excellence in pre-school children with cystic fibrosis

Receiving results of uncertain clinical relevance from population genetic screening: systematic review & meta-synthesis of qualitative research

Future therapies for cystic fibrosis

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Cystic Fibrosis Transmembrane Conductance Regulator-Related Metabolic Syndrome and Cystic Fibrosis Screen Positive, Inconclusive Diagnosis

Macrolide antibiotics for cystic fibrosis

Safety, pharmacokinetics, and pharmacodynamics of ivacaftor in patients aged 2–5 years with cystic fibrosis and a CFTR gating mutation (KIWI): an open-label, single-arm study

Impact of COVID-19 on people with cystic fibrosis

Raised Intracranial Pressure in Three Children with Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-Ivacaftor Modulator Therapy

ECFS best practice guidelines: the 2018 revision

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)

COVID-19 infection in children

Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis

Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

Exercise versus airway clearance techniques for people with cystic fibrosis

Development and validation of a short form psychometric tool assessing the caregiving Challenge of Living with Cystic Fibrosis (CLCF-SF) in a child

Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis

Parental decision-making and acceptance of newborn bloodspot screening: an exploratory study

Suchergebnisse filtern